Paolo Mannelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Paolo Mannelli has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Li-Tzy Wu
Department of Psychiatry & Behavioral Sciences; Department of Medicine (Division of General Internal Medicine), Duke University Medical Center; Duke Clinical Research Institute; Center for Child & Family Policy, Sanford School of Public Policy, Duke University, Durham, NC, USA
9 shared publicationsKathleen Peindl
7 shared publications- Li-Tzy Wu
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, USA
5 shared publications Ashwin A. Patkar
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
4 shared publicationsDavid A. Gorelick
Chemistry & Drug Metabolism Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD
4 shared publicationsLi‐Tzy Wu
Department of Psychiatry and Behavioral Sciences Duke University Medical Center Durham NC USA
4 shared publications
Latest Publications
- 2 January 2025
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 51 (1) , 1-3
The role of negative thinking and catastrophizing in the ordinary experience of withdrawal from substances
- 2 January 2025
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 51 (1) , 1-3
The role of negative thinking and catastrophizing in the ordinary experience of withdrawal from substances
- Open Access
- 9 February 2022
- Published by Wiley in The American Journal on Addictions
- Vol. 31 (2) , 142-147
Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
Background and Objectives: Treatment for individuals receiving medication for opioid use disorder (MOUD) should follow an informed patient‐centered approach. To better support patient autonomy in the decision‐making process, clinicians should be aware of patient preferences and be prepared to educate and assist patients in transitioning from one MOUD to another, when clinically indicated. This posthoc analysis describes the characteristics of clinical trial participants (NCT02696434) with a history of opioid use disorder (OUD) seeking to transition from buprenorphine (BUP) to extended‐release naltrexone (XR‐NTX).Methods: The posthoc analysis included adults with OUD currently receiving BUP (≤8 mg/day) and seeking transition to XR‐NTX (N = 101) in a residential setting. Baseline participant characteristics and OUD treatment history were reviewed. All patients completed a screening questionnaire that asked about their reasons for seeking transition to XR‐NTX and for choosing BUP.Results: The most common reasons for initiating a transition to XR‐NTX were “Seeking to be opioid‐free” (63.4%) and “Tired of daily pill taking” (25.7%). Positive predictors of transition included a more extensive BUP treatment history and a history of prescription opioid abuse. Most participants stated they were not aware of XR‐NTX as a treatment option when initiating BUP (78.2%).Discussions and Conclusions: Patients' reasons for seeking XR‐NTX transition, more extensive BUP treatment history, and a history of prescription opioid abuse, may positively predict outcomes.Scientific Significance: These findings may assist clinicians in optimizing outcomes of the BUP to XR‐NTX transition and supporting patients to make better informed MOUD decisions.
- 9 February 2022
- Published by Wiley in The American Journal on Addictions
- Vol. 31 (2) , 142-147
Open AccessCharacteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
Background and Objectives: Treatment for individuals receiving medication for opioid use disorder (MOUD) should follow an informed patient‐centered approach. To better support patient autonomy in the decision‐making process, clinicians should be aware of patient preferences and be prepared to educate and assist patients in transitioning from one MOUD to another, when clinically indicated. This posthoc analysis describes the characteristics of clinical trial participants (NCT02696434) with a history of opioid use disorder (OUD) seeking to transition from buprenorphine (BUP) to extended‐release naltrexone (XR‐NTX).Methods: The posthoc analysis included adults with OUD currently receiving BUP (≤8 mg/day) and seeking transition to XR‐NTX (N = 101) in a residential setting. Baseline participant characteristics and OUD treatment history were reviewed. All patients completed a screening questionnaire that asked about their reasons for seeking transition to XR‐NTX and for choosing BUP.Results: The most common reasons for initiating a transition to XR‐NTX were “Seeking to be opioid‐free” (63.4%) and “Tired of daily pill taking” (25.7%). Positive predictors of transition included a more extensive BUP treatment history and a history of prescription opioid abuse. Most participants stated they were not aware of XR‐NTX as a treatment option when initiating BUP (78.2%).Discussions and Conclusions: Patients' reasons for seeking XR‐NTX transition, more extensive BUP treatment history, and a history of prescription opioid abuse, may positively predict outcomes.Scientific Significance: These findings may assist clinicians in optimizing outcomes of the BUP to XR‐NTX transition and supporting patients to make better informed MOUD decisions.
- Open Access
- 2 November 2021
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 47 (6) , 753-759
Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone
Pharmacologic treatment is recommended for many individuals with opioid use disorder (OUD). For patients who select opioid antagonist treatment, effective management of opioid withdrawal symptoms during transition to antagonist treatment requires consideration of the patient experience. To compare patterns of opioid withdrawal between those withdrawing from untreated opioid use and those withdrawing from buprenorphine. We performed a post hoc, cross-study comparison of the temporal pattern of opioid withdrawal during 1-week induction onto extended-release naltrexone by similar protocols enrolling two participant populations: participants with OUD entering a study with untreated opioid use (N = 378, NCT02537574) or on stable buprenorphine (BUP) treatment (N = 101, NCT02696434). The temporal pattern of withdrawal from induction day 1 through day 7 differed between the two participant populations for Clinical Opiate Withdrawal Score (COWS) and Subjective Opiate Withdrawal Score (SOWS): participants with untreated OUD prior to study entry were more likely to experience an earlier relative peak in opioid withdrawal followed by a gradual decline, whereas participants on stable BUP treatment prior to study entry were more likely to experience a relatively later, though still mild, peak opioid withdrawal. The peak COWS was reached at a mean (standard deviation) of 1.9 (1.5) days for participants with untreated OUD and 5.0 (1.5) days for participants on stable BUP. Daily peak cravings were generally higher for participants with untreated OUD than participants on stable BUP. Awareness of population-specific variations in the patient experience of opioid withdrawal may help clinicians anticipate the expected course of withdrawal.
- 2 November 2021
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 47 (6) , 753-759
Open AccessPatterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone
Pharmacologic treatment is recommended for many individuals with opioid use disorder (OUD). For patients who select opioid antagonist treatment, effective management of opioid withdrawal symptoms during transition to antagonist treatment requires consideration of the patient experience. To compare patterns of opioid withdrawal between those withdrawing from untreated opioid use and those withdrawing from buprenorphine. We performed a post hoc, cross-study comparison of the temporal pattern of opioid withdrawal during 1-week induction onto extended-release naltrexone by similar protocols enrolling two participant populations: participants with OUD entering a study with untreated opioid use (N = 378, NCT02537574) or on stable buprenorphine (BUP) treatment (N = 101, NCT02696434). The temporal pattern of withdrawal from induction day 1 through day 7 differed between the two participant populations for Clinical Opiate Withdrawal Score (COWS) and Subjective Opiate Withdrawal Score (SOWS): participants with untreated OUD prior to study entry were more likely to experience an earlier relative peak in opioid withdrawal followed by a gradual decline, whereas participants on stable BUP treatment prior to study entry were more likely to experience a relatively later, though still mild, peak opioid withdrawal. The peak COWS was reached at a mean (standard deviation) of 1.9 (1.5) days for participants with untreated OUD and 5.0 (1.5) days for participants on stable BUP. Daily peak cravings were generally higher for participants with untreated OUD than participants on stable BUP. Awareness of population-specific variations in the patient experience of opioid withdrawal may help clinicians anticipate the expected course of withdrawal.
- 1 May 2021
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 29 (5) , 426-428
Heroin Use in Older Adults: A Treatment Challenge
- 1 May 2021
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 29 (5) , 426-428
Heroin Use in Older Adults: A Treatment Challenge
Buprenorphine physician–pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network
Background and Aims: Physician and pharmacist collaboration may help address the shortage of buprenorphine‐waivered physicians and improve care for patients with opioid use disorder (OUD). This study investigated the feasibility and acceptability of a new collaborative care model involving buprenorphine‐waivered physicians and community pharmacists.Design: Nonrandomized, single‐arm, open‐label feasibility trial.Setting: Three office‐based buprenorphine treatment (OBBT) clinics and three community pharmacies in the United States.Participants: Six physicians, six pharmacists, and 71 patients aged ≥18 years with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5) OUD on buprenorphine maintenance.Intervention: After screening, eligible patients’ buprenorphine care was transferred from their OBBT physician to a community pharmacist for 6 months.Measurements: Primary outcomes included recruitment, treatment retention and adherence, and opioid use. Secondary outcomes were intervention fidelity, pharmacists' use of prescription drug monitoring program (PDMP), participant safety, and satisfaction with treatment delivery.Findings: A high proportion (93.4%, 71/76) of eligible participants enrolled into the study. There were high rates of treatment retention (88.7%) and adherence (95.3%) at the end of the study. The proportion of opioid‐positive urine drug screens (UDSs) among complete cases (i.e. those with all six UDSs collected during 6 months) at month 6 was (4.9%, 3/61). Intervention fidelity was excellent. Pharmacists used PDMP at 96.8% of visits. There were no opioid‐related safety events. Over 90% of patients endorsed that they were “very satisfied with their experience and the quality of treatment offered,” that “treatment transfer from physician's office to the pharmacy was not difficult at all,” and that “holding buprenorphine visits at the same place the medication is dispensed was very or extremely useful/convenient.” Similarly, positive ratings of satisfaction were found among physicians/pharmacists.Conclusions: A collaborative care model for people with opioid use disorder that involves buprenorphine‐waivered physicians and community pharmacists appears to be feasible to operate in the United States and have high acceptability to patients.
Buprenorphine physician–pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network
Background and Aims: Physician and pharmacist collaboration may help address the shortage of buprenorphine‐waivered physicians and improve care for patients with opioid use disorder (OUD). This study investigated the feasibility and acceptability of a new collaborative care model involving buprenorphine‐waivered physicians and community pharmacists.Design: Nonrandomized, single‐arm, open‐label feasibility trial.Setting: Three office‐based buprenorphine treatment (OBBT) clinics and three community pharmacies in the United States.Participants: Six physicians, six pharmacists, and 71 patients aged ≥18 years with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5) OUD on buprenorphine maintenance.Intervention: After screening, eligible patients’ buprenorphine care was transferred from their OBBT physician to a community pharmacist for 6 months.Measurements: Primary outcomes included recruitment, treatment retention and adherence, and opioid use. Secondary outcomes were intervention fidelity, pharmacists' use of prescription drug monitoring program (PDMP), participant safety, and satisfaction with treatment delivery.Findings: A high proportion (93.4%, 71/76) of eligible participants enrolled into the study. There were high rates of treatment retention (88.7%) and adherence (95.3%) at the end of the study. The proportion of opioid‐positive urine drug screens (UDSs) among complete cases (i.e. those with all six UDSs collected during 6 months) at month 6 was (4.9%, 3/61). Intervention fidelity was excellent. Pharmacists used PDMP at 96.8% of visits. There were no opioid‐related safety events. Over 90% of patients endorsed that they were “very satisfied with their experience and the quality of treatment offered,” that “treatment transfer from physician's office to the pharmacy was not difficult at all,” and that “holding buprenorphine visits at the same place the medication is dispensed was very or extremely useful/convenient.” Similarly, positive ratings of satisfaction were found among physicians/pharmacists.Conclusions: A collaborative care model for people with opioid use disorder that involves buprenorphine‐waivered physicians and community pharmacists appears to be feasible to operate in the United States and have high acceptability to patients.
- Open Access
- 4 April 2020
- Published by Wiley in The American Journal on Addictions
- Vol. 29 (4) , 313-322
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
Background and Objective: When patients seek to discontinue buprenorphine (BUP) treatment, monthly injectable extended‐release naltrexone (XR‐NTX) may help them avoid relapse. The efficacy of low ascending doses of oral NTX vs placebo for patients transitioning from BUP to XR‐NTX is evaluated in this study.Methods: In a phase 3, hybrid residential/outpatient study, clinically stable participants with opioid use disorder (N = 101), receiving BUP for more than or equal to 3 months and seeking antagonist treatment, were randomized (1:1) to 7 residential days of descending doses of BUP and low ascending doses of oral NTX (NTX/BUP, n = 50) or placebo (PBO‐N/BUP, n = 51). Both groups received standing ancillary medications and psychoeducational counseling. Following negative naloxone challenge, participants received XR‐NTX (day 8). The primary endpoint was the proportion of participants who received and tolerated XR‐NTX.Results: There was no statistical difference between groups for participants receiving a first dose of XR‐NTX: 68.6% (NTX/BUP) vs 76.0% (PBO‐N/BUP; P = .407). The mean number of days with peak Clinical Opiate Withdrawal Scale (COWS) score less than or equal to 12 during the treatment period (days 1‐7) was similar for NTX/BUP and PBO‐N/BUP groups (5.8 vs 6.3; P = .511). Opioid withdrawal symptoms during XR‐NTX induction and post‐XR‐NTX observation period (days 8‐11) were mild and similar between groups (mean peak COWS score: NTX/BUP, 5.1 vs PBO‐N/BUP, 5.4; P = .464). Adverse events were mostly mild/moderate.Conclusions and Scientific Significance: Low ascending doses of oral NTX did not increase induction rates onto XR‐NTX compared with placebo. The overall rate of successful induction across treatment groups supports a brief BUP taper with standing ancillary medications as a well‐tolerated approach for patients seeking transition from BUP to XR‐NTX. (Am J Addict 2020;00:00–00)
- 4 April 2020
- Published by Wiley in The American Journal on Addictions
- Vol. 29 (4) , 313-322
Open AccessTransition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
Background and Objective: When patients seek to discontinue buprenorphine (BUP) treatment, monthly injectable extended‐release naltrexone (XR‐NTX) may help them avoid relapse. The efficacy of low ascending doses of oral NTX vs placebo for patients transitioning from BUP to XR‐NTX is evaluated in this study.Methods: In a phase 3, hybrid residential/outpatient study, clinically stable participants with opioid use disorder (N = 101), receiving BUP for more than or equal to 3 months and seeking antagonist treatment, were randomized (1:1) to 7 residential days of descending doses of BUP and low ascending doses of oral NTX (NTX/BUP, n = 50) or placebo (PBO‐N/BUP, n = 51). Both groups received standing ancillary medications and psychoeducational counseling. Following negative naloxone challenge, participants received XR‐NTX (day 8). The primary endpoint was the proportion of participants who received and tolerated XR‐NTX.Results: There was no statistical difference between groups for participants receiving a first dose of XR‐NTX: 68.6% (NTX/BUP) vs 76.0% (PBO‐N/BUP; P = .407). The mean number of days with peak Clinical Opiate Withdrawal Scale (COWS) score less than or equal to 12 during the treatment period (days 1‐7) was similar for NTX/BUP and PBO‐N/BUP groups (5.8 vs 6.3; P = .511). Opioid withdrawal symptoms during XR‐NTX induction and post‐XR‐NTX observation period (days 8‐11) were mild and similar between groups (mean peak COWS score: NTX/BUP, 5.1 vs PBO‐N/BUP, 5.4; P = .464). Adverse events were mostly mild/moderate.Conclusions and Scientific Significance: Low ascending doses of oral NTX did not increase induction rates onto XR‐NTX compared with placebo. The overall rate of successful induction across treatment groups supports a brief BUP taper with standing ancillary medications as a well‐tolerated approach for patients seeking transition from BUP to XR‐NTX. (Am J Addict 2020;00:00–00)
- Open Access
Commentary on Winhusen et al . (2019): Substance use disorders, chronic diseases, and electronic health records—a paradigm for screening and intervention
Click on the article title to read more.
Open AccessCommentary on Winhusen et al . (2019): Substance use disorders, chronic diseases, and electronic health records—a paradigm for screening and intervention
Click on the article title to read more.
- Open Access
- 1 April 2019
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 149 (4) , 443-445
Clinical epidemiology of substance use disorders
- 1 April 2019
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 149 (4) , 443-445
Open AccessClinical epidemiology of substance use disorders
- 8 March 2019
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 45 (3) , 227-229
Opioid use disorder deaths and the effects of medication therapy
(2019). Opioid use disorder deaths and the effects of medication therapy. The American Journal of Drug and Alcohol Abuse: Vol. 45, No. 3, pp. 227-229.
- 8 March 2019
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 45 (3) , 227-229
Opioid use disorder deaths and the effects of medication therapy
(2019). Opioid use disorder deaths and the effects of medication therapy. The American Journal of Drug and Alcohol Abuse: Vol. 45, No. 3, pp. 227-229.